Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Consensus Recommendation of “Hold” by Analysts

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) has been assigned a consensus recommendation of “Hold” from the five brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $41.00.

ETON has been the subject of several research reports. B. Riley Financial increased their price target on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a research report on Friday, March 20th. HC Wainwright increased their price target on shares of Eton Pharmaceuticals from $52.00 to $57.00 and gave the company a “buy” rating in a research report on Friday, May 15th. Zacks Research lowered shares of Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 17th. Craig Hallum increased their price target on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, March 20th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Tuesday, April 21st.

Eton Pharmaceuticals Stock Performance

NASDAQ ETON opened at $32.48 on Tuesday. Eton Pharmaceuticals has a 1 year low of $13.09 and a 1 year high of $35.66. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.21 and a quick ratio of 0.88. The firm has a market cap of $889.63 million, a price-to-earnings ratio of -463.93 and a beta of 0.87. The company has a fifty day moving average price of $29.07 and a 200-day moving average price of $21.67.

Eton Pharmaceuticals (NASDAQ:ETON) last posted its earnings results on Thursday, May 14th. The company reported $0.05 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.05). Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%.The firm had revenue of $24.27 million during the quarter, compared to the consensus estimate of $22.31 million. As a group, equities research analysts predict that Eton Pharmaceuticals will post 0.75 EPS for the current fiscal year.

Insider Activity

In related news, insider David Krempa sold 42,797 shares of the stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $33.39, for a total transaction of $1,428,991.83. Following the completion of the transaction, the insider owned 25,249 shares in the company, valued at approximately $843,064.11. This represents a 62.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jennifer Mckie Adams sold 50,000 shares of the stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the transaction, the director owned 50,000 shares of the company’s stock, valued at approximately $1,624,000. The trade was a 50.00% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 150,000 shares of company stock valued at $4,853,921. 16.49% of the stock is owned by company insiders.

Institutional Investors Weigh In On Eton Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the business. Quarry LP purchased a new stake in Eton Pharmaceuticals during the third quarter valued at about $37,000. Caitong International Asset Management Co. Ltd purchased a new stake in Eton Pharmaceuticals during the fourth quarter valued at about $44,000. Legal & General Group Plc purchased a new stake in Eton Pharmaceuticals during the second quarter valued at about $41,000. China Universal Asset Management Co. Ltd. purchased a new stake in Eton Pharmaceuticals during the fourth quarter valued at about $74,000. Finally, SG Americas Securities LLC purchased a new stake in Eton Pharmaceuticals during the fourth quarter valued at about $109,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.